Kytril

Granisetron, the active ingredient in Kytril, is a 5‑HT3 receptor antagonist presented as an oral tablet for oral use. It is employed to prevent nausea and vomiting caused by chemotherapy or surgery in adult patients. It is indicated for both chemotherapy‑induced and postoperative nausea and vomiting, offering an effective option for supportive care in cancer treatment protocols.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Kytril (granisetron) is used to control nausea and vomiting by targeting the serotonergic pathway in several clinical settings.

Chemotherapy‑induced nausea and vomiting: prevents and treats acute and delayed nausea and vomiting associated with cytotoxic chemotherapy in adult patients. Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures, improving patient recovery. Radiation therapy‑induced nausea and vomiting: helps control nausea and vomiting that may occur during or after radiotherapy treatments.

Granisetron may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements or hard stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or low energy.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias, especially in patients with pre‑existing heart conditions. - Severe allergic reaction: signs include rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare but possible when combined with other serotonergic agents, presenting with agitation, hyperthermia, or neuromuscular abnormalities.

When prescribing Kytril, clinicians should consider several precautionary measures to ensure patient safety. - Cardiac assessment: evaluate baseline ECG and correct electrolyte imbalances before use. - Hepatic function: use cautiously in patients with severe liver impairment; dose adjustment may be required. - Drug hypersensitivity: avoid in individuals with known allergy to granisetron or other 5‑HT3 antagonists. - Concomitant QT‑prolonging agents: monitor closely or avoid combined use to reduce arrhythmia risk. - Pregnancy and lactation: limited data; prescribe only if potential benefit justifies potential risk. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Granisetron can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomorphine: concurrent use may cause severe hypotension and loss of consciousness. - Other 5‑HT3 antagonists: combined use can increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise granisetron plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure. - QT‑prolonging drugs (e.g., quinidine, haloperidol): require ECG monitoring. - Opioid analgesics: may enhance antiemetic effect but also increase sedation.